Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

7

Portfolio Exits

6

About Eric Hahn

Eric Hahn is an angel investor who generally invests $50K-$250K in young, emerging companies with a focus on companies in the Silicon Valley - San Francisco geographies. He invests primarily in seed opportunities and some in post-seed. He looks for companies with high IP content and likes freemium and SaaS-subscription based models vs ad supported ones. Favorite areas of focus include messaging, mobile, social and infrastructure. Hahn is an active investor and aims to assist portfolio companies through efforts and expertise focused on user advocacy, technology, product development, recruitment and financial and legal matters. Hahn is a Founding Partner at Inventures Group which he led the creation of in 1998. Prior to Inventures, Dr. Hahn was the Founder and CEO at Collabra Software which he founded in 1992 and which was acquired by Netscape in 1995. He formerly served as the Chief Technology Officer at Netscape. Dr. Hahn has degrees from Worcester Polytechnic Institute.

Eric Hahn Headquarters Location

Palo Alto, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Eric Hahn News

Progress MN: Takeda Pharmaceutical Co. Limited

Apr 8, 2016

Pharmaceutical giant Takeda’s new Brooklyn Park facility will focus on manufacturing its drug Entyvio, which is used to treat ulcerative colitis and Crohn’s disease. Submitted photo Progress MN: Takeda Pharmaceutical Co. Limited By: Dan Heilman April 8, 20161:25 am 0 Business: Pharmaceutical products Based: 9960-9992 Winnetka Ave. N., Brooklyn Park (Minnesota headquarters) Founded: 1781 Senior director: Eric Hahn, senior director and site head, biologics operations and engineering (in charge of manufacturing and operations in Minnesota) Employee count: 42 currently at Brooklyn Park site Website: www.takeda.us Sometimes the right property comes along at the right time. That was the case for the Minnesota division of Takeda, the Japan-based pharmaceutical giant, when it found a 215,000-square-foot building in Brooklyn Park that had previously been occupied by Baxalta, a spinoff company of Baxter International. The purpose of the purchase was to help Takeda internalize some of its biologics manufacturing, according to Erich Hahn, who runs Takeda’s Minnesota manufacturing operations. The site in Brooklyn Park represented a place for Takeda to manufacture its drug Entyvio, which is used to treat ulcerative colitis and Crohn’s disease – as well as to create work for more than 40 people from Baxter, with 150 more hires planned over the next two years. “The facility is state-of-the-art and an excellent fit in terms of scale and capabilities to produce Entyvio,” said Hahn. “The facility is designed for multi-product operation, which is important for Takeda as we look at flexibility and growth.” The purchase was serendipitous as not only was Baxter looking to get rid of it, but state, city and academic entities were eager to bring Takeda in. According to Hahn, the company plans to complete facility modifications next year, followed by FDA paperwork to allow drug manufacturing at the facility, with commercial approval expected in 2019. Share this:

Eric Hahn Investments

7 Investments

Eric Hahn has made 7 investments. Their latest investment was in Wit.ai as part of their Seed VC on October 10, 2014.

CBI Logo

Eric Hahn Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/15/2014

Seed VC

Wit.ai

$3M

Yes

2

4/24/2014

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/23/2013

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

1/10/2013

Seed VC

Subscribe to see more

$99M

Subscribe to see more

0

7/19/2012

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/15/2014

4/24/2014

7/23/2013

1/10/2013

7/19/2012

Round

Seed VC

Seed VC

Seed VC - II

Seed VC

Series A

Company

Wit.ai

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

0

0

Eric Hahn Portfolio Exits

6 Portfolio Exits

Eric Hahn has 6 portfolio exits. Their latest portfolio exit was Content Analytics on April 09, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/9/2019

Acquired

$99M

1

5/6/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/8/2015

Acq - Talent

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/12/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/9/2019

5/6/2015

3/8/2015

1/5/2015

3/12/2012

Exit

Acquired

Acquired

Acq - Talent

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

0

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.